CompletedPhase 3NCT01226459
Clinical Trial in Females for Female Pattern Hair Loss
Studying Alopecia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
- Principal Investigator
- Clare Kendall, PharmDJohnson & Johnson Consumer and Personal Products Worldwide
- Intervention
- 5% Minoxidil Topical Foam(drug)
- Enrollment
- 404 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2010 – 2011
Study locations (16)
- Axis Clinical Trials, Los Angeles, California, United States
- Therapeutics Clinical Research, San Diego, California, United States
- Heartland Research Associates LLC, Wichita, Kansas, United States
- Callender Skin & Laser Center, Glenn Dale, Maryland, United States
- Michigan Center for Skin Care Research, Clinton Township, Michigan, United States
- Minnesota Clinical Study Center, Fridley, Minnesota, United States
- New York University School of Medicine, New York, New York, United States
- Derm Research Center of New York, Stony Brook, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- J&S Studies, Inc., College Station, Texas, United States
- David A. Whiting, MD PA, Dallas, Texas, United States
- The Education & Research Foundation Inc, Lynchburg, Virginia, United States
- Hôpital Saint Jacques Service de Dermatologie, Besançon, France
- Clinical Research Center for Hair and Skin Science Universitätsmedizin Berlin, Berlin, Germany
- Dermaticum Practice for Dermatology, Freiburg im Breisgau, Germany
- +1 more locations on ClinicalTrials.gov
Collaborators
Johnson & Johnson Consumer and Personal Products Worldwide
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01226459 on ClinicalTrials.govOther trials for Alopecia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07487948Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT07533006A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)Eli Lilly and Company
- ENROLLING BY INVITATIONNCT07499713Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia AreataIstanbul Training and Research Hospital
- RECRUITINGPHASE3NCT07435012Androgenic Alopecia TH07 Clinical TrialTriple Hair Inc
- RECRUITINGNANCT07422376Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands RegionCharles Mays
- RECRUITINGNCT07226531Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USPfizer
- RECRUITINGNANCT07563036JAK2 Expression in Androgenetic Alopecia Before and After Topical MinoxidilKasr El Aini Hospital
- RECRUITINGPHASE2NCT07370519Topical Application of Lactobacillus Reuteri for Androgenetic AlopeciaShenzhen People's Hospital